All In Biotech

Drug Trial Radar · NCT00785785

A Study of Nilotinib Versus Imatinib in GIST Patients

A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)

Last checked: Nov 19, 2026Latest source record: Jun 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 644 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

644

Actual

Start

Mar 2009

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).

Conditions

  • Gastrointestinal Stromal Tumor (GIST)

Interventions

  • Nilotinib (AMN107)Drug

  • imatinib (STI571)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Progression Free Survival (PFS)Time frame: up to month 37

Locations

165 sites in 35 countries. Site status is shown where the registry gives one.

  • Birmingham Hematology and Oncology Associates

    Birmingham, Alabama

  • Northern Arizona Hematology/Oncology Associates, P.C. Dept. of No. AZ Hem-Onc

    Flagstaff, Arizona

  • City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(4)

    Duarte, California

  • City of Hope National Medical Center Regulatory Document

    Duarte, California

  • University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (2)

    La Jolla, California

  • University of California at Los Angeles GI Oncology Program

    Los Angeles, California

  • Stanford University Medical Center Stanford Cancer Center

    Stanford, California

  • University of Colorado Dept. of Univ. of Colorado

    Aurora, Colorado

  • Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer

    Greenwood Village, Colorado

  • Washington Hospital Center Wash Hospital

    Washington D.C., District of Columbia

  • Ocala Oncology Center Dept. of Ocala Oncology Center

    Ocala, Florida

  • Kootenai Medical Center Dept.ofKootenai Med.Ctr.

    Coeur d'Alene, Idaho

  • Northwestern University Clinical Research Office (2)

    Chicago, Illinois

  • Dana Farber Cancer Institute Centerfor Sarcoma&BoneOncology

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center DeptofMichiganCancerCenter(6)

    Ann Arbor, Michigan

  • Minnesota Oncology Hematology, P.A. SC

    Minneapolis, Minnesota

  • Mayo Clinic - Rochester Division of Hematology

    Rochester, Minnesota

  • New York Oncology Hematology, P.C. NYOH Amsterdam

    Troy, New York

  • New York Oncology Hematology, P.C. NYOH@AlbanyMedicalCenter(2)

    Troy, New York

  • University of Pennsylvania Medical Center CAMN107G2301

    Philadelphia, Pennsylvania

  • Vanderbilt Univeristy Ingram Cancer Ctr.

    Nashville, Tennessee

  • Texas Oncology, P.A. Tex Onc (2)

    Bedford, Texas

  • Texas Oncology Wichita Falls

    Dallas, Texas

  • University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(3)

    Dallas, Texas

  • University of Texas/MD Anderson Cancer Center Dept. of MD Anderson (13)

    Houston, Texas

  • Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)

    San Antonio, Texas

  • Tyler Cancer Center Dept.ofTylerCancerCtr. (2)

    Tyler, Texas

  • University of Utah / Huntsman Cancer Institute Dept.ofHuntsmanCancerInst.(3)

    Salt Lake City, Utah

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Leoben, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Wels, Austria

  • Novartis Investigative Site

    Innsbruck, Tyrol, Austria

  • Novartis Investigative Site

    Uberlândia, Minas Gerais, Brazil

  • Novartis Investigative Site

    Florianópolis, Santa Catarina, Brazil

  • Novartis Investigative Site

    Campinas, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

Showing 40 of 165 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.